Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.

Leleu X, Kyriakou C, Vande Broek I, Murphy P, Bacon P, Lewis P, Gilet H, Arnould B, Petrucci MT.

Blood Cancer J. 2017 Mar 17;7(3):e543. doi: 10.1038/bcj.2017.20.

2.

Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.

Decoster L, Vande Broek I, Neyns B, Majois F, Baurain JF, Rottey S, Rorive A, Anckaert E, De Mey J, De Brakeleer S, De Grève J.

Anticancer Res. 2015 Dec;35(12):6893-9.

PMID:
26637913
3.

Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients.

Xu S, Cecilia Santini G, De Veirman K, Vande Broek I, Leleu X, De Becker A, Van Camp B, Vanderkerken K, Van Riet I.

PLoS One. 2013 Nov 6;8(11):e79752. doi: 10.1371/journal.pone.0079752. eCollection 2013.

4.

Continuous treatment in multiple myeloma: the future?

Vande Broek I, Jacobs P.

Transfus Apher Sci. 2013 Oct;49(2):147-50. doi: 10.1016/j.transci.2013.07.017. Epub 2013 Sep 24. Review.

PMID:
24074557
5.

Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians.

Caers J, Vekemans MC, Bries G, Beel K, Delrieu V, Deweweire A, Demuynck H, De Prijck B, De Samblanx H, Kentos A, Meuleman N, Mineur P, Offner F, Vande Broek I, Van Droogenbroeck J, Vande Velde A, Wu KL, Delforge M, Schots R, Doyen C; Multiple Myeloma Study Group of the Belgian Hematological Society.

Ann Med. 2013 Sep;45(5-6):413-22. doi: 10.3109/07853890.2013.801562. Epub 2013 Jun 14. Review.

PMID:
23767978
6.

Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo.

Xu S, De Veirman K, Evans H, Santini GC, Vande Broek I, Leleu X, De Becker A, Van Camp B, Croucher P, Vanderkerken K, Van Riet I.

Acta Pharmacol Sin. 2013 May;34(5):699-709. doi: 10.1038/aps.2012.182. Epub 2013 Apr 8.

7.

Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway.

Xu S, Evans H, Buckle C, De Veirman K, Hu J, Xu D, Menu E, De Becker A, Vande Broek I, Leleu X, Camp BV, Croucher P, Vanderkerken K, Van Riet I.

Leukemia. 2012 Dec;26(12):2546-9. doi: 10.1038/leu.2012.126. Epub 2012 May 8. No abstract available.

PMID:
22652628
8.

PDS5A, a novel translocation partner of MLL in acute myeloid leukemia.

Put N, Van Roosbroeck K, Vande Broek I, Michaux L, Vandenberghe P.

Leuk Res. 2012 Apr;36(4):e87-9. doi: 10.1016/j.leukres.2011.12.006. Epub 2012 Jan 9. No abstract available.

PMID:
22230297
9.

Effect of sample dilution on serum free light chain concentration by immunonephelometric assay.

Vercammen M, Meirlaen P, Broodtaerts L, Vande Broek I, Bossuyt X.

Clin Chim Acta. 2011 Sep 18;412(19-20):1798-804. doi: 10.1016/j.cca.2011.06.021. Epub 2011 Jun 29.

PMID:
21740895
10.

The Belgian 2010 consensus recommendations for the treatment of multiple myeloma.

Schots R, Delforge M, André M, Bries G, Caers J, Demuynck H, De Prijck B, De Samblanx H, Kentos A, Meuleman N, Offner F, Vekemans MC, Vande Broek I, Van Droogenbroeck J, Van de Vanelde A, Wu KL, Doyen C; Multiple Myeloma Study Group of the Belgian Hematological Society.

Acta Clin Belg. 2010 Jul-Aug;65(4):252-64.

PMID:
20954465
11.

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.

Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart CP, Vanderkerken K.

Blood. 2010 Sep 2;116(9):1524-7. doi: 10.1182/blood-2010-02-269126. Epub 2010 Jun 7.

12.

Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disorders.

Vermeersch P, Vercammen M, Holvoet A, Vande Broek I, Delforge M, Bossuyt X.

Clin Chim Acta. 2009 Dec;410(1-2):54-8. doi: 10.1016/j.cca.2009.09.021. Epub 2009 Sep 22. Erratum in: Clin Chim Acta. 2010 Apr 2;411(7-8):613. Broeck, Isabelle Vande [corrected to Vande Broek, Isabelle].

PMID:
19778527
13.

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, De Raeve H, Coulton L, Van Camp B, Croucher P, Vanderkerken K.

Cancer Res. 2009 Jul 1;69(13):5307-11. doi: 10.1158/0008-5472.CAN-08-4472. Epub 2009 Jun 16.

14.

The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models.

Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, King P, Vande Broek I, De Raeve H, Van Camp B, Croucher P, Vanderkerken K.

Leukemia. 2009 Oct;23(10):1894-903. doi: 10.1038/leu.2009.121. Epub 2009 Jun 4.

PMID:
19494837
15.

Fatal cerebral zygomycosis breakthrough in a patient with acute lymphoblastic leukemia on voriconazole prophylaxis after cord blood SCT.

Vande Broek I, Schots R.

Bone Marrow Transplant. 2009 Dec;44(11):765-6. doi: 10.1038/bmt.2009.74. Epub 2009 May 4. No abstract available.

PMID:
19421169
16.

Multiple myeloma--an update on diagnosis and treatment.

Caers J, Vande broek I, De Raeve H, Michaux L, Trullemans F, Schots R, Van Camp B, Vanderkerken K.

Eur J Haematol. 2008 Nov;81(5):329-43. doi: 10.1111/j.1600-0609.2008.01127.x. Epub 2008 Sep 13. Review.

PMID:
18637123
17.

Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival.

De Bruyne E, Bos TJ, Asosingh K, Vande Broek I, Menu E, Van Valckenborgh E, Atadja P, Coiteux V, Leleu X, Thielemans K, Van Camp B, Vanderkerken K, Van Riet I.

Clin Cancer Res. 2008 May 15;14(10):2918-26. doi: 10.1158/1078-0432.CCR-07-4489.

18.

Extravasation and homing mechanisms in multiple myeloma.

Vande Broek I, Vanderkerken K, Van Camp B, Van Riet I.

Clin Exp Metastasis. 2008;25(4):325-34. Epub 2007 Oct 19. Review.

PMID:
17952614
19.

Migration of culture-expanded human mesenchymal stem cells through bone marrow endothelium is regulated by matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-3.

De Becker A, Van Hummelen P, Bakkus M, Vande Broek I, De Wever J, De Waele M, Van Riet I.

Haematologica. 2007 Apr;92(4):440-9.

20.

The involvement of stromal derived factor 1alpha in homing and progression of multiple myeloma in the 5TMM model.

Menu E, Asosingh K, Indraccolo S, De Raeve H, Van Riet I, Van Valckenborgh E, Vande Broek I, Fujii N, Tamamura H, Van Camp B, Vanderkerken K.

Haematologica. 2006 May;91(5):605-12. Epub 2006 Apr 19. Erratum in: Haematologica. 2007 Nov;92(11):1584. Van de Broek, Isabelle [corrected to Vande Broek, Isabelle].

21.

Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival.

Vande Broek I, Leleu X, Schots R, Facon T, Vanderkerken K, Van Camp B, Van Riet I.

Haematologica. 2006 Feb;91(2):200-6. Erratum in: Haematologica. 2007 Nov;92(11):1584. Van de Broek, Isabelle [corrected to Vande Broek, Isabelle].

22.

Bone marrow endothelial cells increase the invasiveness of human multiple myeloma cells through upregulation of MMP-9: evidence for a role of hepatocyte growth factor.

Vande Broek I, Asosingh K, Allegaert V, Leleu X, Facon T, Vanderkerken K, Van Camp B, Van Riet I.

Leukemia. 2004 May;18(5):976-82.

PMID:
14999296
23.
24.

Mechanisms involved in the differential bone marrow homing of CD45 subsets in 5T murine models of myeloma.

Asosingh K, Menu E, Van Valckenborgh E, Vande Broek I, Van Riet I, Van Camp B, Vanderkerken K.

Clin Exp Metastasis. 2002;19(7):583-91.

PMID:
12498387
25.

Multiple myeloma, a model for fundamental and clinical research.

Vande Broek I, Asosingh K, Vanderkerken K, Van Riet I, Van Camp B.

Verh K Acad Geneeskd Belg. 2002;64(4):261-84; discussion 284-6. Review.

PMID:
12416235
26.

Extramedullary plasmacytoma of the cavernous sinus.

Vande Broek I, Stadnik T, Meurs A, Maes J, Van Camp B, Schots R.

Leuk Lymphoma. 2002 Aug;43(8):1691-3.

PMID:
12400615
27.

Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T multiple myeloma cells.

Vanderkerken K, Vande Broek I, Eizirik DL, Van Valckenborgh E, Asosingh K, Van Riet I, Van Camp B.

Clin Exp Metastasis. 2002;19(1):87-90.

PMID:
11918087
28.

Laminin-1-induced migration of multiple myeloma cells involves the high-affinity 67 kD laminin receptor.

Vande Broek I, Vanderkerken K, De Greef C, Asosingh K, Straetmans N, Van Camp B, Van Riet I.

Br J Cancer. 2001 Nov 2;85(9):1387-95.

29.

Homing of the myeloma cell clone.

Vanderkerken K, Van Camp B, De Greef C, Vande Broek I, Asosingh K, Van Riet I.

Acta Oncol. 2000;39(7):771-6.

PMID:
11145431
30.

Selective initial in vivo homing pattern of 5T2 multiple myeloma cells in the C57BL/KalwRij mouse.

Vanderkerken K, De Greef C, Asosingh K, Arteta B, De Veerman M, Vande Broek I, Van Riet I, Kobayashi M, Smedsrod B, Van Camp B.

Br J Cancer. 2000 Feb;82(4):953-9.

Supplemental Content

Loading ...
Support Center